Show simple item record

dc.contributor.authorChauveau, Fabien; orcid: 0000-0002-4177-741X; email: chauveau@cermep.fr
dc.contributor.authorBecker, Guillaume; orcid: 0000-0002-1714-0267
dc.contributor.authorBoutin, Hervé; orcid: 0000-0002-0029-5246; email: herve.boutin@manchester.ac.uk
dc.date.accessioned2021-08-27T00:46:47Z
dc.date.available2021-08-27T00:46:47Z
dc.date.issued2021-08-13
dc.date.submitted2021-02-25
dc.identifierpubmed: 34387719
dc.identifierdoi: 10.1007/s00259-021-05425-w
dc.identifierpii: 10.1007/s00259-021-05425-w
dc.identifier.citationEuropean journal of nuclear medicine and molecular imaging
dc.identifier.urihttp://hdl.handle.net/10034/625703
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: received 2021-02-25, accepted 2021-05-19
dc.descriptionPublication status: aheadofprint
dc.descriptionFunder: Agence Nationale de la Recherche; Grant(s): ANR-15-CE17-0020
dc.description.abstractThe prototypical TSPO radiotracer (R)-[ C]PK11195 has been used in humans for more than thirty years to visualize neuroinflammation in several pathologies. Alternative radiotracers have been developed to improve signal-to-noise ratio and started to be tested clinically in 2008. Here we examined the scientific value of these "(R)-[ C]PK11195 challengers" in clinical research to determine if they could supersede (R)-[ C]PK11195. A systematic MEDLINE (PubMed) search was performed (up to end of year 2020) to extract publications reporting TSPO PET in patients with identified pathologies, excluding studies in healthy subjects and methodological studies. Of the 288 publications selected, 152 used 13 challengers, and 142 used (R)-[ C]PK11195. Over the last 20 years, the number of (R)-[ C]PK11195 studies remained stable (6 ± 3 per year), but was surpassed by the total number of challenger studies for the last 6 years. In total, 3914 patients underwent a TSPO PET scan, and 47% (1851 patients) received (R)-[ C]PK11195. The 2 main challengers were [ C]PBR28 (24%-938 patients) and [ F]FEPPA (11%-429 patients). Only one-in-ten patients (11%-447) underwent 2 TSPO scans, among whom 40 (1%) were scanned with 2 different TSPO radiotracers. Generally, challengers confirmed disease-specific initial (R)-[ C]PK11195 findings. However, while their better signal-to-noise ratio seems particularly useful in diseases with moderate and widespread neuroinflammation, most challengers present an allelic-dependent (Ala147Thr polymorphism) TSPO binding and genetic stratification is hindering their clinical implementation. As new challengers, insensitive to TSPO human polymorphism, are about to enter clinical evaluation, we propose this systematic review to be regularly updated (living review). [Abstract copyright: © 2021. The Author(s).]
dc.languageeng
dc.sourceeissn: 1619-7089
dc.subjectClinical PET imaging
dc.subjectRadiotracer
dc.subject(R)-[11C]PK11195
dc.subjectNeuroinflammation
dc.subjectTranslocator protein 18 kDa (TSPO)
dc.titleHave (R)-[
dc.typearticle
dc.date.updated2021-08-27T00:46:47Z
dc.date.accepted2021-05-19


This item appears in the following Collection(s)

Show simple item record